Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration.
aflibercept
age-related macular degeneration
choroidal thickness
pachychoroid neovasculopathy
Journal
Clinical ophthalmology (Auckland, N.Z.)
ISSN: 1177-5467
Titre abrégé: Clin Ophthalmol
Pays: New Zealand
ID NLM: 101321512
Informations de publication
Date de publication:
2021
2021
Historique:
received:
04
10
2020
accepted:
24
02
2021
entrez:
22
4
2021
pubmed:
23
4
2021
medline:
23
4
2021
Statut:
epublish
Résumé
To compare the 12-month efficacy of intravitreous aflibercept (IVA) injection between eyes with pachychoroid neovasculopathy and neovascular age-related macular degeneration (AMD). Retrospective, comparative case series analysis. Twenty-seven eyes with pachychoroid neovasculopathy and sixty-three eyes with neovascular AMD. All patients received three initial monthly, followed by bimonthly, IVA injections. Twelve months after initial treatment, the mean best-corrected visual acuity (BCVA) had improved both in pachychoroid neovasculopathy (from 0.28 to 0.14 logMAR; Periodic IVA injection leads to anatomical and functional improvement in eyes with pachychoroid neovasculopathy and in eyes with neovascular AMD.
Identifiants
pubmed: 33883872
doi: 10.2147/OPTH.S285257
pii: 285257
pmc: PMC8054474
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1539-1549Informations de copyright
© 2021 Elfandi et al.
Déclaration de conflit d'intérêts
None of the authors has a proprietary interest in any of the products described herein. Dr Manabu Miyata reports personal fees from Santen Pharmaceutical, personal fees from HOYA, grants from Alcon Japan, grants from Novartis Pharma, outside the submitted work. Dr Hiroshi Tamura reports personal fees from Novartis, grants from Findex, and personal fees from Suntory, outside the submitted work. Dr Akio Oishi reports personal fees from Bayer and non-financial support from Tokai Optical, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
Ophthalmology. 2008 Jun;115(6):1026-31
pubmed: 17981333
Ophthalmology. 2014 Jan;121(1):193-201
pubmed: 24084500
Retina. 2015 Jan;35(1):1-9
pubmed: 25158945
Am J Ophthalmol. 2017 Feb;174:160-168
pubmed: 27746298
Retina. 2009 Nov-Dec;29(10):1469-73
pubmed: 19898183
Retina. 2013 Sep;33(8):1659-72
pubmed: 23751942
N Engl J Med. 2006 Oct 5;355(14):1432-44
pubmed: 17021319
Ophthalmology. 2013 Jan;120(1):175-80
pubmed: 23009895
Am J Ophthalmol. 2015 Apr;159(4):627-33
pubmed: 25555799
Am J Physiol. 1998 Mar;274(3):H1054-8
pubmed: 9530221
Trans Am Ophthalmol Soc. 1986;84:799-845
pubmed: 3590481
Retina. 2006 Oct;26(8):859-70
pubmed: 17031284
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Ophthalmology. 2016 Mar;123(3):617-24
pubmed: 26686967
Invest Ophthalmol Vis Sci. 2014 Nov 13;55(12):7874-80
pubmed: 25395483
Prog Retin Eye Res. 2016 Jan;50:1-24
pubmed: 26307399
Med Hypothesis Discov Innov Ophthalmol. 2014 Winter;3(4):111-5
pubmed: 25756060
Retina. 2012 Oct;32(9):1829-37
pubmed: 22850219
Am J Ophthalmol. 1999 Jul;128(1):63-8
pubmed: 10482095
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):292-298
pubmed: 28114590
Ophthalmology. 2004 Feb;111(2):244-9
pubmed: 15019370
Am J Ophthalmol. 2013 Apr;155(4):720-6, 726.e1
pubmed: 23317653
Br J Ophthalmol. 2009 May;93(5):622-6
pubmed: 19208677
Ophthalmology. 2009 Jan;116(1):57-65.e5
pubmed: 19118696
Am J Ophthalmol. 2008 Oct;146(4):496-500
pubmed: 18639219
Am J Ophthalmol. 2001 Nov;132(5):668-81
pubmed: 11704028
Sci Rep. 2015 Nov 06;5:16204
pubmed: 26542071
Ophthalmol Retina. 2018 Apr;2(4):295-305
pubmed: 31047238
Exp Eye Res. 2007 Oct;85(4):425-30
pubmed: 17714704
Ophthalmology. 2012 Dec;119(12):2537-48
pubmed: 23084240
Am J Ophthalmol. 2015 May;159(5):853-60.e1
pubmed: 25634529
Retina. 2015 Jan;35(1):10-6
pubmed: 25046398
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):4129-34
pubmed: 26114491
Br J Ophthalmol. 2015 Oct;99(10):1341-4
pubmed: 25877895
Retina. 2011 Sep;31(8):1627-36
pubmed: 21606888
Am J Ophthalmol. 2014 Aug;158(2):362-371.e2
pubmed: 24794091
Retina. 2016 Mar;36(3):499-516
pubmed: 26335436
Invest Ophthalmol Vis Sci. 2018 Feb 1;59(2):1119-1124
pubmed: 29490349
Jpn J Ophthalmol. 2018 Mar;62(2):144-150
pubmed: 29411171
Sci Rep. 2020 Oct 1;10(1):16248
pubmed: 33004959
Retina. 2016 Jan;36(1):1-8
pubmed: 26414957
Am J Ophthalmol. 2009 May;147(5):811-5
pubmed: 19232559